SERPE, ROBERTO
 Distribuzione geografica
Continente #
EU - Europa 100.761
NA - Nord America 5.843
AS - Asia 2.031
SA - Sud America 342
AF - Africa 34
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 6
AN - Antartide 1
Totale 109.025
Nazione #
IT - Italia 99.182
US - Stati Uniti d'America 5.771
CN - Cina 929
SG - Singapore 759
UA - Ucraina 495
SE - Svezia 357
BR - Brasile 285
DE - Germania 248
GB - Regno Unito 163
FI - Finlandia 132
VN - Vietnam 118
KR - Corea 64
FR - Francia 59
CA - Canada 46
IN - India 26
AR - Argentina 24
RU - Federazione Russa 20
BE - Belgio 18
TR - Turchia 18
HK - Hong Kong 17
IR - Iran 16
PL - Polonia 16
ZA - Sudafrica 15
ES - Italia 13
BD - Bangladesh 12
ID - Indonesia 12
JP - Giappone 11
EC - Ecuador 10
MX - Messico 10
NL - Olanda 9
AT - Austria 8
IE - Irlanda 8
EU - Europa 7
IQ - Iraq 7
PK - Pakistan 7
RS - Serbia 7
AU - Australia 6
BG - Bulgaria 5
KE - Kenya 5
PH - Filippine 5
BO - Bolivia 4
CH - Svizzera 4
CL - Cile 4
JO - Giordania 4
LT - Lituania 4
MA - Marocco 4
RO - Romania 4
SA - Arabia Saudita 4
VE - Venezuela 4
CO - Colombia 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
JM - Giamaica 3
KG - Kirghizistan 3
KZ - Kazakistan 3
PE - Perù 3
TN - Tunisia 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
DZ - Algeria 2
EG - Egitto 2
GT - Guatemala 2
LB - Libano 2
NI - Nicaragua 2
PA - Panama 2
PY - Paraguay 2
TH - Thailandia 2
UZ - Uzbekistan 2
AL - Albania 1
AQ - Antartide 1
AZ - Azerbaigian 1
BW - Botswana 1
EE - Estonia 1
GA - Gabon 1
HU - Ungheria 1
IL - Israele 1
IS - Islanda 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MK - Macedonia 1
ML - Mali 1
MO - Macao, regione amministrativa speciale della Cina 1
NO - Norvegia 1
PR - Porto Rico 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
Totale 109.025
Città #
Cagliari 97.542
Uta 1.364
Woodbridge 599
Fairfield 576
Ashburn 436
Houston 398
Dallas 397
Chandler 390
Singapore 335
Ann Arbor 316
Jacksonville 285
Nyköping 268
Boardman 250
Wilmington 249
Seattle 237
Beijing 226
Dearborn 171
Cambridge 168
Nanjing 85
Boston 79
Los Angeles 70
Hefei 68
New York 68
Santa Clara 61
Seoul 57
Shanghai 54
Helsinki 52
Ho Chi Minh City 46
San Diego 44
Nanchang 35
Buffalo 34
Munich 32
Redwood City 32
Milan 29
Changsha 28
The Dalles 28
Guangzhou 26
Toronto 24
Tianjin 23
Hanoi 22
Hebei 22
Shenyang 21
São Paulo 21
London 20
Jinan 19
Hong Kong 17
Brussels 16
Redondo Beach 16
Verona 16
Norwalk 15
Mountain View 14
Orange 14
Warsaw 14
Zhengzhou 14
Auburn Hills 13
Atlanta 12
Chicago 11
Council Bluffs 11
Jiaxing 10
Phoenix 10
Rome 10
Sassari 10
Tokyo 10
Wuhan 9
Brooklyn 8
Dong Ket 8
Rio de Janeiro 8
Augusta 7
Campinas 7
Dublin 7
Hangzhou 7
Johannesburg 7
Nuremberg 7
Nürnberg 7
San Mateo 7
Stockholm 7
Bielefeld 6
Chennai 6
Columbus 6
Denver 6
Düsseldorf 6
Frankfurt am Main 6
San Francisco 6
Winston-Salem 6
Ankara 5
Baghdad 5
Brasília 5
Charlotte 5
Curitiba 5
Leawood 5
Montreal 5
Nairobi 5
Ninh Bình 5
Poplar 5
Pune 5
Shenzhen 5
Amman 4
Amsterdam 4
Belo Horizonte 4
Bloomington 4
Totale 105.760
Nome #
High-density lipoprotein contribute to G0-G1/S transition in Swiss NIH/3T3 fibroblasts 4.907
Morningness Eveningness Questionnaire (MEQ) and salivary DLMO determination: a reliable method of evaluation for circadian pattern 3.692
Effects of an adapted physical training on functional status, body composition and quality of life in persons with spinal cord injury paraplegia: a pilot study 3.405
Krill Oil supplementation modifies endocannabinoid congeners profile in cachectic advanced cancer patients 3.289
Antimicrobial sulfonamides clear latent Kaposi sarcoma herpesvirus infection and impair MDM2-p53 complex formation 3.245
Cardiovascular effects, body composition, quality of life and pain after a Zumba® fitness program in Italian overweight women 2.921
Effects of a nordic walking program on motor and non-motor symptoms, functional performance and body composition in patients with Parkinson's disease 2.736
Positive effects of Nordic Walking on anthropometric and metabolic variables in women with type 2 diabetes mellitus 2.676
Antimicrobial sulfonamides inhibit Herpesvirus 8 latency by impairing the MDM2-p53 complex formation 2.660
Sulfonamide compounds inhibit latent Human Herpesvirus 8 replication by interfering with MDM2-p53 complex formation 2.513
Randomized phase III clinical trial of a combined treatment with carnitine plus celecoxib +/- megestrol acetate for patients with cancer-related anorexia/cachexia syndrome 2.407
Effects of an adapted physical activity program on motor and non-motor functions and quality of life in patients with Parkinson's disease 2.340
null 2.211
The cachexia score (CASCO) as a tool for staging cachectic cancer patients 2.174
Selenium is effective in inducing lymphocyte progression through cell cycle in cancer patients: potential mechanisms for its activity 2.168
Trastuzumab-based adjuvant chemotherapy for breast cancer: Early myocardial dysfunction detected by "speckle tracking" echocardiography (STE). 2.048
Validation of the CAchexia SCOre (CASCO). Staging cancer patients: The use of miniCASCO as a simplified tool 2.046
Relationship of morningness-eveningness questionnaire score to Melatonin DLMO measured from saliva sample: circadian patterns of a normal subjects group and a delayed phase syndrome 2.044
null 1.987
Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia 1.843
Krill oil to improve blood lipids status in advanced cancer patient with cachexia 1.750
Efficacy and safety of a two drug-combination regimen for cancer-related cachexia in the clinical practice. 1.707
null 1.699
Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia 1.687
Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results 1.684
Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy 1.652
Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers 1.650
Interleukin-1B (IL1B) and interleukin-6 (IL6) gene polymorphisms are associated with risk of chronic lymphocytic leukaemia 1.646
Production of inflammatory molecules in peripheral blood mononuclear cells from severely glucose-6-phosphate dehydrogenase-deficient subjects 1.558
L-Carnitine: An adequate supplement for a multi-targeted anti-wasting therapy in cancer 1.507
Cardioprotective effect of telmisartan in cancer patients treated with telmisartan 1.486
Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers 1.464
Trastuzumab-induced early cardiac dysfunction assessed by speckle tracking echocardiography: correlation with chronic inflammation and oxidative stress markers 1.444
null 1.362
Assessment of adiponectin and leptin as biomarkers of positive metabolic outcomes after lifestyle intervention in overweight and obese children 1.350
EFFICACY AND SAFETY OF A TWO DRUG-COMBINATION REGIMEN FOR CANCER-RELATED CACHEXIA IN THE CLINICAL PRACTICE 1.287
null 1.063
Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress 820
Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters 778
Association of serum IL-6 levels with comprehensive geriatric assessment variables in a population of elderly cancer patients 778
A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress 769
null 768
Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment 767
Cardioprotective effect of telmisartan in cancer patients treated with epirubicin 763
A PHASE II STUDY WITH ANTIOXIDANTS, BOTH IN THE DIET AND SUPPLEMENTED, PHARMACO-NUTRITIONAL SUPPORT,PROGESTAGEN AND ANTI-COX-2 SHOWING EFFICACY AND SAFETY IN PATIENTS WITH CANCER-RELATED ANOREXIA-CACHEXIA AND OXIDATIVE STRESS 755
Current medications for cancer cachexia 740
Formoterol and cancer muscle wasting in rats: Effects on muscle force and total physical activity 724
Antioxidant agents alpha lipoic acid, N-Acetyl cysteine and MESNA (2-mercaptoethane sulfonate) are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients 710
null 709
Early epirubicin-induced myocardail dysfunction revealed by serial tissue doppler echocardiography (TDI). Correlation with inflammatory and oxidative stress markers 704
Cancer cachexia: Physical activity and muscle force in tumour-bearing rats 702
null 694
Cardioprotective effect of Telmisartan in cancer patients treated with Epirubicin 677
Early epirubicin (EPI)-induced myocardial dysfunction revealed by serial tissue doppler imaging (TDI): Correlation with inflammatory and oxidative stress markers 671
Muscle wasting in cancer and ageing: Cachexia versus sarcopenia 665
Improvement of physical activity as an alternative objective variable to measure treatment effects of anticachexia therapy in cancer patients 664
The cachexia score (CASCO): a new tool for staging cachectic cancer patients 652
Randomised Phase III Clinical Trial of a Combined Treatment With Carnitine plus Celecoxib +/- Megestrol Acetate for Patients With Cancer-related Anorexia/cachexia Syndrome 634
null 572
Megestrol acetate: Its impact on muscle protein metabolism supports its use in cancer cachexia 565
A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS) and oxidative stress (OS) 539
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS): Interim results 537
Antioxidant therapy for the treatment of oxidative stress associated to cancer and cancer-related anorexia/cachexia 516
Phase II study with antioxidants, both in the diet and supplemented pharmaco-nutritional support, progestagen and anti-cox-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS) and oxidative stress (OS) 505
Cancer related anorexia/cachexia (CACS) and oxidative stress: an innovative approach beyond current treatment 496
Cancer related anorexia/cachexia (CACS) and oxidative stress: an innovative approach beyond current treatment 496
A phase II study with antioxidants, both in the diet an supplemented, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia-cachexia and oxidative stress 490
Correlation between both serum osteopontin/osteonectin and bone remodelling parameters, inflammatory/metabolic variables and survival in metastatic cancer patients with tumors at different sites 471
Prevention of head and neck squamous cell carcinoma. Integrated treatment approach with diet, pharmaco-nutritional support, antioxidants, and cis-retinoic acid. A phase II study. 470
Phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS). and oxidative stress (OS) 470
null 465
Effects Of An Adapted Physical Training On Functional And Psycho-physical Status In Patients With Spinal Cord Injury 463
null 450
Prevention of head and neck squamous cell carcinoma. integrated treatment approach with diet, pharmaco-nutritional support, antioxidants (and anti-COX-2): preliminary results of a phase II study 435
An innovative approach to CACS 425
null 413
Randomised phase III clinical trial to evaluate the efficacy and safety of an integrated treatment (diet, pharmaco-nutrional and pharmacological) in cancer patients with cancer-related anorexia/cachexia and oxidative stress: interim results 397
Efficacy of L-carnitine administration on fatigue, quality of life and nutritional status in 12 advanced cancer patients undergoing anticancer therapy 392
null 390
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS) 389
null 342
An innovative treatment approach for cancer-related anorexia/cachexia and oxidative stress: Background and design of an ongoing, phase III, randomized clinical trial 310
null 304
Randomised phase III clinical trial to evaluate the efficacy and safety of an integrated treatment (diet, pharmaco-nutritional and pharmacological) in cancer patients with cancer-related anorexia/cachexia and oxidative stress: Interim results 300
Impact of a two-drug combination regimen for cancer-related cachexia on nutritional, anabolic/metabolic, physical activity, anti-infammatory and quality of life variables 284
MESNA (2-mercaptoethane sulfonate) is effective in inducing lymphocyte progression through cell cycle in patients with advanced cancer of different sites 279
Curcuma Longa extract is effective in improving inflammatory status and redox balance in patients with cancer-related cachexia and oxidative stress 270
null 267
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS): Interim results 253
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS) 232
null 208
An innovative treatment approach for cancer-related anorexia/cachexia (CACS) and oxidative stress (OS). A phase III randomised clinical trial 183
Prognostic role of lipid profile in patients with advanced cancer 181
An innovative treatment approach for cancer-related anorexia/cachexia (CACS) and oxidative stress (OS) 177
null 147
A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS) and oxidative stress (OS) 131
Cancer related anorexia/cachexia and oxidative stress: A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 128
Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia 126
Cancer-related anorexia/cachexia (CACS) and oxidative stress (OS): A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 121
Focus on the assessment of physical activity level of patients with cancer cachexia enrolled in a randomized phase III clinical trial 114
Totale 109.155
Categoria #
all - tutte 140.783
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 140.783


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202110.094 0 0 0 0 0 2.916 2.334 1.545 579 1.152 1.027 541
2021/20224.262 401 314 179 296 465 341 175 187 353 439 550 562
2022/20235.508 491 659 689 447 465 528 254 459 355 379 464 318
2023/20246.816 445 336 335 511 693 1.312 839 473 311 467 584 510
2024/20258.457 1.040 1.647 1.329 1.267 700 1.116 564 104 185 126 184 195
2025/20262.295 300 238 677 435 347 298 0 0 0 0 0 0
Totale 109.223